AKBA — Akebia Therapeutics Share News
0.000.00%
Last trade - 00:00- $305.81m
- $337.17m
- $236.20m
Akebia Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months
U.S. STOCKS ON THE MOVE-Accenture, Nike, FedEx
U.S. STOCKS ON THE MOVE-KKR, Micron Technology, Eli Lilly
U.S. STOCKS ON THE MOVE-Five Below, QXO, PDD Holdings
U.S. STOCKS ON THE MOVE-Accenture, Coty, Optinose
Akebia Therapeutics tumbles on deep-discounted $50 mln stock sale
Brief: Akebia Therapeutics Announces Pricing Of Public Offering Of Common Stock
Brief: Akebia Therapeutics announces proposed public offering of common stock
Akebia Therapeutics dives on stock offering plans
Akebia Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Akebia Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: U.S. Renal Care Enrolls First Patients In The Voice Collaborative Clinical Trial Of Vafseo® (Vadadustat) For CKD Patients On Dialysis
Akebia Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Akebia Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Akebia Therapeutics Signs Commercial Supply Contract With Leading Dialysis Organization To Enable Access To Vafseo(Vadadustat)
Brief: Akebia Therapeutics & STA Entered Into Amendment Ž1 To Supply Agreement